
India's homegrown Covid-19 vaccine has 78% efficacy against symptomatic infections, developer says
CNN
Pharmaceutical company Bharat Biotech announced it had concluded the final analysis of its Phase 3 clinical trials, which it called the largest Covid-19 vaccine trial in India.
The trial involved 25,800 participants aged 18 to 98. Of those, 2,433 people were over 60 years old, and 4,500 had comorbidities.
More Related News

Defense Secretary Pete Hegseth risked compromising sensitive military information that could have endangered US troops through his use of Signal to discuss attack plans, a Pentagon watchdog said in an unclassified report released Thursday. It also details how Hegseth declined to cooperate with the probe.












